1.98 0.00 (0.00%)
After hours: 4:59PM EDT
|Bid||1.95 x 1100|
|Ask||2.02 x 4000|
|Day's Range||1.90 - 2.02|
|52 Week Range||1.55 - 6.19|
|Beta (3Y Monthly)||2.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Anyone researching Agenus Inc (NASDAQ:AGEN) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. InvestorsRead More...
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.
Zacks.com featured highlights include: Dollar Tree, Agenus, Huntsman, ArcelorMittal and International Paper
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Agenus (AGEN) delivered earnings and revenue surprises of 36.84% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 24 cents. The company's shares closed at $1.75. A year ago, they were trading at $3.85. _____ This story was generated ...
In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.
Biotechs are infamous for tapping the public markets for capital on a regular basis. Here is a look at how this standard practice can both damage and create value for shareholders.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A few FDA approvals and the impending 2018 American Society of Clinical Oncology annual meeting gave some impetus to the biotech space in the week ending June 1. The FDA greenlighted Pfizer Inc. (NYSE: ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 8) CONMED Corporation (NASDAQ: CNMD ) Enanta Pharmaceuticals Inc ...
Agenus (AGEN) incurs wider-than-expected loss in Q1 and did not report any revenues during the quarter. The company expects to file six investigational new drugs in 2018.